MedWatch

Analyst calls Orphazyme's 300 percent value jump "strange and noteworthy"

Danish biotech company Orphazyme experienced a dramatic value increase on the US stock exchange on Thursday, with trading of the share suspended 20 times. Nordnet analyst Per Hansen calls the increase illogical.

Photo: BRENDAN MCDERMID/REUTERS / X90143

On Thursday, Danish biotech company Orphazyme experienced a dramatic value jump on the US stock exchange.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs